Laboratoire HIFIH, UPRES EA 3859, IFR 132, Université d'Angers, PRES LUNAM, Angers, France.
Ann Intensive Care. 2013 May 22;3(1):13. doi: 10.1186/2110-5820-3-13.
This review aimed to answer whether the vasopressors are useful at the early phase of hemorrhagic shock. Data were taken from published experimental studies and clinical trials. Published case reports were discarded. A search of electronic database PubMed was conducted using keywords of hemorrhagic shock, vasopressors, vasoconstrictors, norepinephrine, epinephrine, vasopressin. The redundant papers were not included. We identified 15 experimental studies that compared hemorrhagic shock resuscitated with or without vasopressors, three retrospective clinical studies, and one controlled trial. The experimental and clinical studies are discussed in the clinical context, and their strengths as well as limitations are highlighted. There is a strong rationale for a vasopressor support in severe hemorrhagic shock. However, this should be tempered by the risk of excessive vasoconstriction during such hypovolemic state. The experimental models must be analyzed within their own limits and cannot be directly translated into clinical practice. In addition, because of many biases, the results of clinical trials are debatable. Therefore, based on current information, further clinical trials comparing early vasopressor support plus fluid resuscitation versus fluid resuscitation alone are warranted.
这篇综述旨在回答血管加压素在失血性休克早期是否有用。数据取自已发表的实验研究和临床试验。已发表的病例报告被排除在外。使用关键词“失血性休克、血管加压素、血管收缩剂、去甲肾上腺素、肾上腺素、血管加压素”在电子数据库 PubMed 中进行了检索。未包括冗余论文。我们确定了 15 项比较使用或不使用血管加压素复苏失血性休克的实验研究、3 项回顾性临床研究和 1 项对照试验。在临床背景下讨论了实验和临床研究,并强调了它们的优势和局限性。在严重失血性休克中,使用血管加压素支持有很强的理由。然而,在这种低血容量状态下,血管过度收缩的风险必须加以考虑。实验模型必须在其自身的限制内进行分析,不能直接转化为临床实践。此外,由于存在许多偏倚,临床试验的结果存在争议。因此,根据目前的信息,有必要进行比较早期血管加压素支持加液体复苏与单纯液体复苏的进一步临床试验。